Other OTC - Delayed Quote • USD
Sienna Biopharmaceuticals, Inc. (SNNAQ)
As of March 25 at 2:22 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2019) | Next Qtr. (Dec 2019) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.82 | -0.93 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2019) | Next Qtr. (Dec 2019) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2018 | 12/31/2018 | 3/31/2019 | 6/30/2019 |
|---|---|---|---|---|
| EPS Est. | -0.79 | -0.83 | -0.5 | -0.4 |
| EPS Actual | -0.82 | -0.93 | -0.67 | -0.27 |
| Difference | -0.03 | -0.1 | -0.17 | 0.13 |
| Surprise % | -3.80% | -12.00% | -34.00% | 32.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2019) | Next Qtr. (Dec 2019) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.24 | -0.22 | -3.5 | -3.1 |
| 30 Days Ago | -0.24 | -0.22 | -3.5 | -3.1 |
| 60 Days Ago | -0.24 | -0.22 | -3.5 | -3.1 |
| 90 Days Ago | -0.24 | -0.22 | -3.5 | -3.1 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2019) | Next Qtr. (Dec 2019) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | -- | -- |
| Up Last 30 Days | 1 | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SNNAQ | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.50% |
| Next Qtr. | -- | -- | -- | 11.40% |
| Current Year | -- | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | BMO Capital: Outperform | 9/5/2019 |
| Downgrade | JP Morgan: Overweight to Neutral | 5/13/2019 |
| Maintains | BMO Capital: Outperform to Outperform | 12/4/2018 |
| Maintains | BMO Capital: Outperform to Outperform | 8/1/2018 |
| Initiated | Guggenheim: Neutral | 12/6/2017 |
| Initiated | Cowen & Co.: Outperform | 8/21/2017 |